Shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded down 1.4% during trading on Thursday . The stock traded as low as $61.57 and last traded at $61.91, with a volume of 272,737 shares trading hands. The stock had previously closed at $62.82.

Several analysts have recently commented on the company. Zacks Investment Research raised Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, April 25th. Piper Jaffray Cos. reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, May 26th. Jefferies Group reissued a “buy” rating and issued a $80.00 price target (down from $119.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, June 8th. Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, April 14th. Finally, Cowen and Company reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, April 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $117.82.

The company’s market capitalization is $5.39 billion. The firm has a 50-day moving average of $62.31 and a 200-day moving average of $65.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Monday, May 2nd. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.16. The firm had revenue of $7.30 million for the quarter, compared to the consensus estimate of $7.79 million. The company’s revenue for the quarter was down 60.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.62) earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals Inc. will post ($4.94) EPS for the current fiscal year.

In related news, CEO John Maraganore sold 30,151 shares of the stock in a transaction that occurred on Wednesday, April 20th. The shares were sold at an average price of $67.46, for a total value of $2,033,986.46. Following the completion of the transaction, the chief executive officer now owns 148,465 shares of the company’s stock, valued at approximately $10,015,448.90. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

A number of institutional investors recently modified their holdings of ALNY. Sei Investments Co. increased its position in shares of Alnylam Pharmaceuticals by 493.7% in the fourth quarter. Sei Investments Co. now owns 19,569 shares of the biopharmaceutical company’s stock valued at $1,842,000 after buying an additional 16,273 shares during the last quarter. TD Asset Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 11.5% in the fourth quarter. TD Asset Management Inc. now owns 21,300 shares of the biopharmaceutical company’s stock valued at $2,005,000 after buying an additional 2,200 shares during the last quarter. Mutual of America Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 0.4% in the fourth quarter. Mutual of America Capital Management LLC now owns 21,637 shares of the biopharmaceutical company’s stock valued at $2,037,000 after buying an additional 87 shares during the last quarter. Gulf International Bank UK Ltd increased its position in shares of Alnylam Pharmaceuticals by 1.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 23,100 shares of the biopharmaceutical company’s stock valued at $2,175,000 after buying an additional 220 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of Alnylam Pharmaceuticals by 18.3% in the fourth quarter. Nationwide Fund Advisors now owns 56,508 shares of the biopharmaceutical company’s stock valued at $5,320,000 after buying an additional 8,742 shares during the last quarter.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.